RA drug sarilumab fares well in study

... Drug Administration approved a new treatment for the disease, Pfizer Inc.'s twice-a-day pill Xeljanz. Shares of Tarrytown, N.Y.-based Regeneron closed at $276.41 on Thursday and have climbed more than 62 percent this year. U.S.-traded shares of ...

http://www.thedenverchannel.com/money/business-news/sanofi-regeneron-drug-fares-well-in-study_54913937_